Aimmune Therapeutics Inc (NASDAQ:AIMT) price target set to $80.00 by Roth Capital

Analyst Ratings For Aimmune Therapeutics Inc (NASDAQ:AIMT)

Story continues below

Today, Roth Capital set its price target on Aimmune Therapeutics Inc (NASDAQ:AIMT) to $80.00 per share.

There are 8 Buy Ratings, 2 Hold Ratings, no Strong Buy Ratings, no Sell Ratings on the stock.

The current consensus rating on Aimmune Therapeutics Inc (NASDAQ:AIMT) is Buy with a consensus target price of $51.5010 per share, a potential 129.92% upside.

Some recent analyst ratings include

  • 12/13/2018-Aimmune Therapeutics Inc (NASDAQ:AIMT) has coverage initiated with a Neutral rating and $32.00 price target
  • 5/18/2018-Aimmune Therapeutics Inc (NASDAQ:AIMT) has coverage initiated with a Overweight rating and $30.01 price target
  • On 11/19/2018 Jayson Donald Alexander Dallas, Insider, bought 3,650 with an average share price of $27.56 per share and the total transaction amounting to $100,594.00.
  • On 6/13/2018 Eric Bjerkholt, CFO, bought 1,600 with an average share price of $30.41 per share and the total transaction amounting to $48,656.00.
  • On 6/11/2018 Stephen George Dilly, CEO, sold 29,457 with an average share price of $30.83 per share and the total transaction amounting to $908,159.31.
  • On 6/8/2018 Stephen George Dilly, Insider, sold 105,169 with an average share price of $30.92 per share and the total transaction amounting to $3,251,825.48.
  • On 6/5/2018 Stephen George Dilly, Insider, sold 165,374 with an average share price of $32.14 per share and the total transaction amounting to $5,315,120.36.
  • On 6/1/2018 Stephen George Dilly, Insider, sold 61,197 with an average share price of $32.62 per share and the total transaction amounting to $1,996,246.14.
  • On 5/22/2018 Douglas T. Sheehy, Insider, sold 3,296 with an average share price of $33.00 per share and the total transaction amounting to $108,768.00.

About Aimmune Therapeutics Inc (NASDAQ:AIMT)
Aimmune Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy product candidate is AR101, an investigational biologic for the treatment of patients with peanut allergy. The company has strategic collaboration with an affiliate of Nestle Health Science US Holdings, Inc. for the advancement of food allergy therapeutics. The company was formerly known as Allergen Research Corporation and changed its name to Aimmune Therapeutics, Inc. in May 2015. Aimmune Therapeutics, Inc. was founded in 2011 and is headquartered in Brisbane, California.

Recent Trading Activity for Aimmune Therapeutics Inc (NASDAQ:AIMT)
Shares of Aimmune Therapeutics Inc closed the previous trading session at 22,42 −1,00 4,27 % with 22.03 shares trading hands.

An ad to help with our costs